- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Dompé Enrolls First Patient in Cerebral Palsy NGF Study
The new clinical trial is investigating an intranasal nerve growth factor treatment for cerebral palsy.
Mar. 30, 2026 at 10:37am
Got story updates? Submit your updates here. ›
Dompé, a biopharmaceutical company, has announced the enrollment of the first patient in a new clinical study evaluating an intranasal nerve growth factor (NGF) treatment for cerebral palsy. The study is taking place in San Mateo, California.
Why it matters
Cerebral palsy is a group of disorders that affect a person's ability to move and maintain balance and posture. Current treatments are limited, so new therapeutic approaches like this NGF therapy could provide important benefits for patients if proven effective.
The details
The new clinical trial will assess the safety and efficacy of Dompé's intranasal NGF therapy in patients with cerebral palsy. NGF is a naturally occurring protein that plays a key role in the growth, maintenance, and survival of nerve cells. Dompé hopes that delivering NGF directly to the nasal cavity can help improve motor function in cerebral palsy patients.
- The first patient was enrolled in the study on March 30, 2026.
The players
Dompé
A biopharmaceutical company developing the intranasal NGF therapy for cerebral palsy.
What’s next
Dompé plans to enroll additional patients in the clinical trial over the coming months to further evaluate the safety and efficacy of the NGF treatment.
The takeaway
This new study represents an innovative approach to treating the symptoms of cerebral palsy, a condition that can significantly impact a person's quality of life. If successful, the intranasal NGF therapy could provide a much-needed therapeutic option for cerebral palsy patients.
